Mr. Francis Mandy Joins Nano Labs' Strategic Advisory Board
Mr. Mandy is an Internationally Recognized Expert in Healthcare and Immunology
DETROIT, Feb. 28, 2013 (GLOBE NEWSWIRE) -- Nano Labs Corp. (OTCQB:CTLE), a nanotechnology research and development company focused on creating a portfolio of advanced products that could provide benefits to a variety of industries including consumer products, energy and healthcare, is pleased to announce today that Mr. Francis F. Mandy has joined Nano Labs Strategic Advisory Board.
Mr. Mandy is an internationally recognized expert in the field of HIV and Immunology where he has held a variety of senior positions over the course of a 40 year career, mostly with the Public Health Agency of Canada and its predecessor agencies.
Prior to his retirement from the Canadian Government, Mr. Mandy's most recent position was Chief of the National HIV Immunology Laboratory with the Public Health Agency of Canada. Mr. Mandy has authored 50 publications, most of which are relevant to clinical diagnostics, quality control and quality laboratory management procedures related to HIV and other infectious diseases both in resource poor and rich countries.
Following retirement after a successful career in the public health sector, Mr. Mandy has worked in consulting roles with other public sector agencies around the globe, including CDC, universities and private enterprises, he is an associate editor of an international journal, co-founded a company conducting research in the field of immunology and taken on senior management positions with biotechnology companies.
"I am very proud to join the Company and am excited at the prospect of introducing next-generation thinking and products to my colleagues and networks globally. The core belief of Nano Labs to enhance access to better health and nutrition, and to improve quality of life into everyday products, and create revolutionary new products for me is the most exciting reason to be joining the company," stated Mr. Mandy. "I believe that nanotechnology is changing the face of business - especially in the fields of bioscience and healthcare and I am very much looking forward to being a part of that change."
In addition to joining the Company's Strategic Advisory Board, Mr. Mandy has entered into an agreement with Nano Labs whereby he has been granted 500,000 compensation warrants that may be exercised to purchase common shares of the Company over a 2 year period at a price of $0.52
"On behalf of our management team and shareholders I would like to welcome Mr. Mandy to Nano Labs," stated Mr. Bernardo Chavarria, President of Nano Labs. "We are excited to have Francis join our Strategic Advisory Board as he brings valuable insight and experience into the field of immunology which represents a great opportunity for the advancement and commercialization of our intellectual property in the healthcare field and the business-related applications."
About Nano Labs
Nano Labs Corp. (CTLE) is a nanotechnology company which is able to access resources that encompass nearly 30 years of research and development in nanotechnology as well as hundreds of peer-reviewed and published research papers and other scholarly material. The Company's research and development team of scientists, designers, and engineers is focused on creating a portfolio of advanced products that could provide benefits to a variety of industries including: (i) consumer products, (ii) energy, (iii) materials, and (iv) healthcare. Through the use and integration of proprietary nano compounds, our goal is to evolve common products into new, revolutionary products in order to make the world a better place. Nano Labs shares are traded on the OTC Bulletin Board in the United States under the ticker CTLE. For more information, please visit www.NanoLabs.us.
The Nano Labs Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=16293
Forward looking statements
This press release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 and is subject to the safe harbor created by those laws. These forward-looking statements are based upon a number of assumptions and estimates that are subject to significant uncertainties that involve known and unknown risks, many of which are beyond our control and are not guarantees of future performance. Actual outcomes and results could materially differ from what is expressed, implied, or forecasted in any such forward-looking statements and any such difference may be caused by risk factors listed from time to time in the Company's news releases and/or its filings with the OTC Bulletin Board or as a result of other factors.
CONTACT: Nano Labs Corp.Bernardo Camacho Chavarria
1 (888) 806-2315
Source: Nano Labs Corp.